The Council for International Organizations of Medical Sciences (CIOMS) has issued a draft report detailing a set of best practices to guide the integration of artificial intelligence in pharmacovigilance (PV) activities.
The report was partly prompted by COVID-19, which “emphasized the need for advanced methods in PV, as it has led to a significant rise in safety reports.”
The report is the result of three years of work. In February 2022, the group released a concept paper suggesting the formation of an Expert Working Group XIV to investigate the use of AI in PV. The group consisted of academics, pharmaceutical companies, regulatory authorities, and national and international organizations…
